nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—testicular cancer	0.661	1	CtDrD
Temsirolimus—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0376	0.177	CbGbCtD
Temsirolimus—CYP3A7—Ifosfamide—testicular cancer	0.0376	0.177	CbGbCtD
Temsirolimus—CYP3A5—Ifosfamide—testicular cancer	0.0282	0.133	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—testicular cancer	0.0155	0.0733	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—testicular cancer	0.0135	0.0635	CbGbCtD
Temsirolimus—CYP3A4—Ifosfamide—testicular cancer	0.011	0.0518	CbGbCtD
Temsirolimus—ABCB1—Vinblastine—testicular cancer	0.00974	0.0459	CbGbCtD
Temsirolimus—CYP2D6—Vinblastine—testicular cancer	0.00918	0.0433	CbGbCtD
Temsirolimus—ABCB1—Cisplatin—testicular cancer	0.00893	0.0421	CbGbCtD
Temsirolimus—ABCB1—Etoposide—testicular cancer	0.00877	0.0414	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—testicular cancer	0.00598	0.0282	CbGbCtD
Temsirolimus—CYP3A4—Vinblastine—testicular cancer	0.00583	0.0275	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—testicular cancer	0.0058	0.0273	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—testicular cancer	0.00564	0.0266	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—testicular cancer	0.00526	0.0248	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—testicular cancer	0.00358	0.0169	CbGbCtD
Temsirolimus—MTOR—embryo—testicular cancer	0.000681	0.124	CbGeAlD
Temsirolimus—MTOR—seminal vesicle—testicular cancer	0.00064	0.116	CbGeAlD
Temsirolimus—FKBP1A—seminal vesicle—testicular cancer	0.000575	0.105	CbGeAlD
Temsirolimus—MTOR—gonad—testicular cancer	0.000462	0.084	CbGeAlD
Temsirolimus—FKBP1A—gonad—testicular cancer	0.000416	0.0756	CbGeAlD
Temsirolimus—MTOR—female gonad—testicular cancer	0.000376	0.0683	CbGeAlD
Temsirolimus—FKBP1A—female gonad—testicular cancer	0.000338	0.0614	CbGeAlD
Temsirolimus—MTOR—testis—testicular cancer	0.000333	0.0606	CbGeAlD
Temsirolimus—FKBP1A—testis—testicular cancer	0.0003	0.0545	CbGeAlD
Temsirolimus—MTOR—mTOR signalling—STK11—testicular cancer	0.000269	0.0386	CbGpPWpGaD
Temsirolimus—MTOR—PKB-mediated events—STK11—testicular cancer	0.000261	0.0375	CbGpPWpGaD
Temsirolimus—MTOR—lymph node—testicular cancer	0.000242	0.0439	CbGeAlD
Temsirolimus—FKBP1A—lymph node—testicular cancer	0.000217	0.0395	CbGeAlD
Temsirolimus—MTOR—LKB1 signaling events—STK11—testicular cancer	0.000185	0.0266	CbGpPWpGaD
Temsirolimus—CYP3A5—female gonad—testicular cancer	0.000147	0.0267	CbGeAlD
Temsirolimus—ABCB1—embryo—testicular cancer	0.000142	0.0258	CbGeAlD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000138	0.0197	CbGpPWpGaD
Temsirolimus—ABCB1—seminal vesicle—testicular cancer	0.000133	0.0242	CbGeAlD
Temsirolimus—MTOR—PI3K Cascade—STK11—testicular cancer	0.000128	0.0184	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—STK11—testicular cancer	0.000127	0.0182	CbGpPWpGaD
Temsirolimus—CYP2D6—female gonad—testicular cancer	0.000109	0.0198	CbGeAlD
Temsirolimus—MTOR—IRS-mediated signalling—STK11—testicular cancer	0.000107	0.0154	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—STK11—testicular cancer	0.000104	0.015	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.000104	0.0149	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—STK11—testicular cancer	0.000101	0.0145	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—STK11—testicular cancer	0.000101	0.0145	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	9.99e-05	0.0143	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	9.84e-05	0.0141	CbGpPWpGaD
Temsirolimus—CYP2D6—testis—testicular cancer	9.64e-05	0.0175	CbGeAlD
Temsirolimus—ABCB1—gonad—testicular cancer	9.62e-05	0.0175	CbGeAlD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	9.6e-05	0.0138	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	9.16e-05	0.0132	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—KITLG—testicular cancer	8.87e-05	0.0127	CbGpPWpGaD
Temsirolimus—MTOR—PI3K Cascade—FGFR3—testicular cancer	8.83e-05	0.0127	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—KITLG—testicular cancer	8.66e-05	0.0124	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—KITLG—testicular cancer	8.59e-05	0.0123	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—BCL10—testicular cancer	8.48e-05	0.0122	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	8.39e-05	0.012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—STK11—testicular cancer	8.37e-05	0.012	CbGpPWpGaD
Temsirolimus—ABCB1—female gonad—testicular cancer	7.82e-05	0.0142	CbGeAlD
Temsirolimus—Hypersensitivity—Ifosfamide—testicular cancer	7.43e-05	0.000651	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—testicular cancer	7.42e-05	0.00065	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—testicular cancer	7.41e-05	0.00065	CcSEcCtD
Temsirolimus—MTOR—IRS-mediated signalling—FGFR3—testicular cancer	7.38e-05	0.0106	CbGpPWpGaD
Temsirolimus—Renal failure—Methotrexate—testicular cancer	7.35e-05	0.000644	CcSEcCtD
Temsirolimus—Neutropenia—Epirubicin—testicular cancer	7.34e-05	0.000643	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—testicular cancer	7.34e-05	0.000643	CcSEcCtD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	7.32e-05	0.0105	CbGpPWpGaD
Temsirolimus—Abdominal distension—Doxorubicin—testicular cancer	7.31e-05	0.000641	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—testicular cancer	7.3e-05	0.000639	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—testicular cancer	7.29e-05	0.000639	CcSEcCtD
Temsirolimus—Conjunctivitis—Methotrexate—testicular cancer	7.27e-05	0.000637	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—testicular cancer	7.26e-05	0.000636	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—testicular cancer	7.26e-05	0.000636	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—testicular cancer	7.25e-05	0.000635	CcSEcCtD
Temsirolimus—Asthenia—Ifosfamide—testicular cancer	7.24e-05	0.000634	CcSEcCtD
Temsirolimus—MTOR—IRS-related events—FGFR3—testicular cancer	7.18e-05	0.0103	CbGpPWpGaD
Temsirolimus—Pruritus—Ifosfamide—testicular cancer	7.14e-05	0.000625	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—testicular cancer	7.13e-05	0.000625	CcSEcCtD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	7.12e-05	0.0102	CbGpPWpGaD
Temsirolimus—Weight decreased—Epirubicin—testicular cancer	7.1e-05	0.000622	CcSEcCtD
Temsirolimus—Dyspnoea—Etoposide—testicular cancer	7.1e-05	0.000622	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—testicular cancer	7.08e-05	0.000621	CcSEcCtD
Temsirolimus—Somnolence—Etoposide—testicular cancer	7.08e-05	0.00062	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—testicular cancer	7.06e-05	0.000618	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—testicular cancer	7.04e-05	0.000617	CcSEcCtD
Temsirolimus—Nausea—Bleomycin—testicular cancer	7.01e-05	0.000614	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—testicular cancer	7e-05	0.000613	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—testicular cancer	7e-05	0.000613	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—testicular cancer	7e-05	0.000613	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—testicular cancer	6.99e-05	0.000612	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—testicular cancer	6.94e-05	0.000608	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—testicular cancer	6.94e-05	0.000608	CcSEcCtD
Temsirolimus—ABCB1—testis—testicular cancer	6.93e-05	0.0126	CbGeAlD
Temsirolimus—MTOR—Insulin receptor signalling cascade—FGFR3—testicular cancer	6.93e-05	0.00995	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—FGFR3—testicular cancer	6.93e-05	0.00995	CbGpPWpGaD
Temsirolimus—Decreased appetite—Etoposide—testicular cancer	6.92e-05	0.000607	CcSEcCtD
Temsirolimus—Diarrhoea—Ifosfamide—testicular cancer	6.9e-05	0.000605	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—testicular cancer	6.88e-05	0.000603	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—testicular cancer	6.88e-05	0.000602	CcSEcCtD
Temsirolimus—Body temperature increased—Cisplatin—testicular cancer	6.87e-05	0.000602	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—testicular cancer	6.87e-05	0.000602	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—testicular cancer	6.82e-05	0.000598	CcSEcCtD
Temsirolimus—Constipation—Etoposide—testicular cancer	6.81e-05	0.000597	CcSEcCtD
Temsirolimus—Pain—Etoposide—testicular cancer	6.81e-05	0.000597	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—testicular cancer	6.8e-05	0.000596	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—testicular cancer	6.8e-05	0.000596	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—testicular cancer	6.79e-05	0.000595	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—testicular cancer	6.79e-05	0.000595	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—STK11—testicular cancer	6.78e-05	0.00973	CbGpPWpGaD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—testicular cancer	6.75e-05	0.000592	CcSEcCtD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	6.72e-05	0.00964	CbGpPWpGaD
Temsirolimus—Pollakiuria—Doxorubicin—testicular cancer	6.71e-05	0.000588	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—testicular cancer	6.68e-05	0.000585	CcSEcCtD
Temsirolimus—Dizziness—Ifosfamide—testicular cancer	6.67e-05	0.000584	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—testicular cancer	6.67e-05	0.000584	CcSEcCtD
Temsirolimus—CYP3A7—Biological oxidations—HPGDS—testicular cancer	6.64e-05	0.00953	CbGpPWpGaD
Temsirolimus—Urinary tract disorder—Methotrexate—testicular cancer	6.63e-05	0.000581	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—KITLG—testicular cancer	6.63e-05	0.00951	CbGpPWpGaD
Temsirolimus—Epistaxis—Epirubicin—testicular cancer	6.6e-05	0.000579	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—FGFR3—testicular cancer	6.59e-05	0.00946	CbGpPWpGaD
Temsirolimus—Urethral disorder—Methotrexate—testicular cancer	6.58e-05	0.000577	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—testicular cancer	6.57e-05	0.000576	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—testicular cancer	6.57e-05	0.000575	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—testicular cancer	6.55e-05	0.000574	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—testicular cancer	6.54e-05	0.000573	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—testicular cancer	6.52e-05	0.000571	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—testicular cancer	6.51e-05	0.000571	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—testicular cancer	6.48e-05	0.000568	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—testicular cancer	6.48e-05	0.000568	CcSEcCtD
Temsirolimus—MTOR—PI3K/AKT activation—FGFR3—testicular cancer	6.43e-05	0.00923	CbGpPWpGaD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	6.42e-05	0.000563	CcSEcCtD
Temsirolimus—Vomiting—Ifosfamide—testicular cancer	6.41e-05	0.000562	CcSEcCtD
Temsirolimus—Hypersensitivity—Cisplatin—testicular cancer	6.41e-05	0.000561	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—FGFR3—testicular cancer	6.38e-05	0.00916	CbGpPWpGaD
Temsirolimus—Renal failure—Doxorubicin—testicular cancer	6.37e-05	0.000558	CcSEcCtD
Temsirolimus—Rash—Ifosfamide—testicular cancer	6.36e-05	0.000557	CcSEcCtD
Temsirolimus—Dermatitis—Ifosfamide—testicular cancer	6.35e-05	0.000557	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—testicular cancer	6.35e-05	0.000556	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KITLG—testicular cancer	6.34e-05	0.0091	CbGpPWpGaD
Temsirolimus—Stomatitis—Doxorubicin—testicular cancer	6.31e-05	0.000553	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—testicular cancer	6.3e-05	0.000552	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—testicular cancer	6.3e-05	0.000552	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—testicular cancer	6.3e-05	0.000552	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—testicular cancer	6.3e-05	0.000552	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—testicular cancer	6.3e-05	0.000552	CcSEcCtD
Temsirolimus—Eye disorder—Methotrexate—testicular cancer	6.28e-05	0.00055	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—KITLG—testicular cancer	6.24e-05	0.00896	CbGpPWpGaD
Temsirolimus—Asthenia—Cisplatin—testicular cancer	6.24e-05	0.000547	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—testicular cancer	6.24e-05	0.000546	CcSEcCtD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	6.24e-05	0.00895	CbGpPWpGaD
Temsirolimus—Cardiac disorder—Methotrexate—testicular cancer	6.23e-05	0.000546	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—testicular cancer	6.21e-05	0.000544	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—testicular cancer	6.19e-05	0.000542	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—testicular cancer	6.18e-05	0.000541	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—testicular cancer	6.18e-05	0.000541	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—testicular cancer	6.16e-05	0.00054	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—testicular cancer	6.11e-05	0.000535	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—testicular cancer	6.09e-05	0.000534	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—testicular cancer	6.08e-05	0.000532	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—testicular cancer	6.07e-05	0.000531	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—testicular cancer	6.05e-05	0.00053	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—KIT—testicular cancer	6.05e-05	0.00868	CbGpPWpGaD
Temsirolimus—Chills—Methotrexate—testicular cancer	6.03e-05	0.000528	CcSEcCtD
Temsirolimus—Nausea—Ifosfamide—testicular cancer	5.99e-05	0.000525	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—KITLG—testicular cancer	5.96e-05	0.00855	CbGpPWpGaD
Temsirolimus—Diarrhoea—Cisplatin—testicular cancer	5.95e-05	0.000521	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—testicular cancer	5.94e-05	0.000521	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR—KITLG—testicular cancer	5.93e-05	0.00851	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—KIT—testicular cancer	5.91e-05	0.00848	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KITLG—testicular cancer	5.9e-05	0.00847	CbGpPWpGaD
Temsirolimus—Mental disorder—Methotrexate—testicular cancer	5.88e-05	0.000515	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—testicular cancer	5.87e-05	0.000515	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—KITLG—testicular cancer	5.87e-05	0.00843	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Etoposide—testicular cancer	5.87e-05	0.000514	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—KIT—testicular cancer	5.86e-05	0.00841	CbGpPWpGaD
Temsirolimus—Malnutrition—Methotrexate—testicular cancer	5.85e-05	0.000512	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—testicular cancer	5.85e-05	0.000512	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—testicular cancer	5.83e-05	0.000511	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—testicular cancer	5.83e-05	0.000511	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	5.79e-05	0.00831	CbGpPWpGaD
Temsirolimus—Pharyngitis—Doxorubicin—testicular cancer	5.77e-05	0.000506	CcSEcCtD
Temsirolimus—MTOR—Signaling by Insulin receptor—FGFR3—testicular cancer	5.76e-05	0.00826	CbGpPWpGaD
Temsirolimus—Urinary tract disorder—Doxorubicin—testicular cancer	5.74e-05	0.000503	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—testicular cancer	5.73e-05	0.000502	CcSEcCtD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	5.73e-05	0.00822	CbGpPWpGaD
Temsirolimus—Dysgeusia—Methotrexate—testicular cancer	5.72e-05	0.000502	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—testicular cancer	5.72e-05	0.000501	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—testicular cancer	5.71e-05	0.000501	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—testicular cancer	5.7e-05	0.0005	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—testicular cancer	5.7e-05	0.000499	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—testicular cancer	5.68e-05	0.000497	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—testicular cancer	5.66e-05	0.000496	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—testicular cancer	5.65e-05	0.000495	CcSEcCtD
Temsirolimus—Chills—Epirubicin—testicular cancer	5.64e-05	0.000494	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—testicular cancer	5.64e-05	0.000494	CcSEcCtD
Temsirolimus—Vomiting—Cisplatin—testicular cancer	5.53e-05	0.000484	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	5.53e-05	0.00793	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KITLG—testicular cancer	5.53e-05	0.00793	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KITLG—testicular cancer	5.53e-05	0.00793	CbGpPWpGaD
Temsirolimus—Mental disorder—Epirubicin—testicular cancer	5.51e-05	0.000482	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—testicular cancer	5.5e-05	0.000482	CcSEcCtD
Temsirolimus—Rash—Cisplatin—testicular cancer	5.48e-05	0.00048	CcSEcCtD
Temsirolimus—Dermatitis—Cisplatin—testicular cancer	5.48e-05	0.00048	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—KITLG—testicular cancer	5.48e-05	0.00786	CbGpPWpGaD
Temsirolimus—Malnutrition—Epirubicin—testicular cancer	5.47e-05	0.000479	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—testicular cancer	5.47e-05	0.000479	CcSEcCtD
Temsirolimus—Diarrhoea—Etoposide—testicular cancer	5.45e-05	0.000477	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—testicular cancer	5.43e-05	0.000476	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KITLG—testicular cancer	5.43e-05	0.00779	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KITLG—testicular cancer	5.4e-05	0.00776	CbGpPWpGaD
Temsirolimus—Anaemia—Methotrexate—testicular cancer	5.4e-05	0.000473	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—testicular cancer	5.4e-05	0.000473	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—testicular cancer	5.36e-05	0.000469	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—testicular cancer	5.29e-05	0.000464	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—testicular cancer	5.28e-05	0.000462	CcSEcCtD
Temsirolimus—Dizziness—Etoposide—testicular cancer	5.27e-05	0.000461	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—testicular cancer	5.25e-05	0.00046	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—testicular cancer	5.24e-05	0.000459	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—testicular cancer	5.23e-05	0.000458	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—testicular cancer	5.22e-05	0.000457	CcSEcCtD
Temsirolimus—Nausea—Cisplatin—testicular cancer	5.16e-05	0.000452	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—KITLG—testicular cancer	5.11e-05	0.00734	CbGpPWpGaD
Temsirolimus—Cough—Methotrexate—testicular cancer	5.1e-05	0.000447	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—testicular cancer	5.09e-05	0.000446	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—testicular cancer	5.07e-05	0.000444	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—testicular cancer	5.06e-05	0.000444	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—testicular cancer	5.06e-05	0.000443	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—testicular cancer	5.06e-05	0.000443	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—testicular cancer	5.06e-05	0.000443	CcSEcCtD
Temsirolimus—ABCB1—lymph node—testicular cancer	5.03e-05	0.00913	CbGeAlD
Temsirolimus—Rash—Etoposide—testicular cancer	5.02e-05	0.00044	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—testicular cancer	5.02e-05	0.00044	CcSEcCtD
Temsirolimus—Headache—Etoposide—testicular cancer	4.99e-05	0.000437	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—testicular cancer	4.98e-05	0.000436	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—testicular cancer	4.98e-05	0.000436	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—testicular cancer	4.98e-05	0.000436	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—testicular cancer	4.96e-05	0.000434	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.94e-05	0.000433	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—FGFR3—testicular cancer	4.93e-05	0.00707	CbGpPWpGaD
Temsirolimus—Leukopenia—Epirubicin—testicular cancer	4.9e-05	0.000429	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—testicular cancer	4.9e-05	0.000429	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	4.89e-05	0.00702	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—INSL3—testicular cancer	4.88e-05	0.00701	CbGpPWpGaD
Temsirolimus—CYP3A5—Biological oxidations—HPGDS—testicular cancer	4.8e-05	0.00689	CbGpPWpGaD
Temsirolimus—Cough—Epirubicin—testicular cancer	4.77e-05	0.000418	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—testicular cancer	4.77e-05	0.000418	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—testicular cancer	4.74e-05	0.000415	CcSEcCtD
Temsirolimus—Infection—Methotrexate—testicular cancer	4.74e-05	0.000415	CcSEcCtD
Temsirolimus—Nausea—Etoposide—testicular cancer	4.73e-05	0.000415	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—testicular cancer	4.72e-05	0.000414	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	4.71e-05	0.00676	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Methotrexate—testicular cancer	4.68e-05	0.00041	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—testicular cancer	4.68e-05	0.00041	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—testicular cancer	4.67e-05	0.000409	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—testicular cancer	4.66e-05	0.000408	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—testicular cancer	4.66e-05	0.000408	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—testicular cancer	4.66e-05	0.000408	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—testicular cancer	4.64e-05	0.000407	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—FGFR3—testicular cancer	4.64e-05	0.00666	CbGpPWpGaD
Temsirolimus—Skin disorder—Methotrexate—testicular cancer	4.63e-05	0.000406	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	4.63e-05	0.000405	CcSEcCtD
Temsirolimus—Anorexia—Methotrexate—testicular cancer	4.55e-05	0.000398	CcSEcCtD
Temsirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	4.54e-05	0.00651	CbGpPWpGaD
Temsirolimus—Leukopenia—Doxorubicin—testicular cancer	4.53e-05	0.000397	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—KIT—testicular cancer	4.52e-05	0.00649	CbGpPWpGaD
Temsirolimus—Anaphylactic shock—Epirubicin—testicular cancer	4.47e-05	0.000391	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—testicular cancer	4.47e-05	0.000391	CcSEcCtD
Temsirolimus—Infection—Epirubicin—testicular cancer	4.44e-05	0.000389	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—FGFR3—testicular cancer	4.43e-05	0.00636	CbGpPWpGaD
Temsirolimus—Cough—Doxorubicin—testicular cancer	4.42e-05	0.000387	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR—FGFR3—testicular cancer	4.41e-05	0.00633	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—FGFR3—testicular cancer	4.39e-05	0.0063	CbGpPWpGaD
Temsirolimus—Convulsion—Doxorubicin—testicular cancer	4.39e-05	0.000384	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—testicular cancer	4.38e-05	0.000384	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—testicular cancer	4.37e-05	0.000383	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—testicular cancer	4.37e-05	0.000383	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—FGFR3—testicular cancer	4.36e-05	0.00626	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—H2AFZ—testicular cancer	4.36e-05	0.00626	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—testicular cancer	4.35e-05	0.000381	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—testicular cancer	4.34e-05	0.00038	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KIT—testicular cancer	4.33e-05	0.00621	CbGpPWpGaD
Temsirolimus—Insomnia—Methotrexate—testicular cancer	4.32e-05	0.000378	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—testicular cancer	4.31e-05	0.000378	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—testicular cancer	4.31e-05	0.000378	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—testicular cancer	4.31e-05	0.000378	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	4.3e-05	0.00617	CbGpPWpGaD
Temsirolimus—Anxiety—Doxorubicin—testicular cancer	4.29e-05	0.000376	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	4.28e-05	0.000375	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—KIT—testicular cancer	4.26e-05	0.00611	CbGpPWpGaD
Temsirolimus—Anorexia—Epirubicin—testicular cancer	4.26e-05	0.000373	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—testicular cancer	4.25e-05	0.000373	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—testicular cancer	4.24e-05	0.000372	CcSEcCtD
Temsirolimus—Decreased appetite—Methotrexate—testicular cancer	4.15e-05	0.000363	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—testicular cancer	4.13e-05	0.000362	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—testicular cancer	4.13e-05	0.000362	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—testicular cancer	4.12e-05	0.000361	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—testicular cancer	4.11e-05	0.00036	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	4.11e-05	0.00589	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—FGFR3—testicular cancer	4.11e-05	0.00589	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—FGFR3—testicular cancer	4.11e-05	0.00589	CbGpPWpGaD
Temsirolimus—Infection—Doxorubicin—testicular cancer	4.1e-05	0.00036	CcSEcCtD
Temsirolimus—Pain—Methotrexate—testicular cancer	4.08e-05	0.000357	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—FGFR3—testicular cancer	4.07e-05	0.00584	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—testicular cancer	4.07e-05	0.000356	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—KIT—testicular cancer	4.07e-05	0.00584	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Doxorubicin—testicular cancer	4.05e-05	0.000355	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR—KIT—testicular cancer	4.05e-05	0.00581	CbGpPWpGaD
Temsirolimus—Thrombocytopenia—Doxorubicin—testicular cancer	4.05e-05	0.000354	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—testicular cancer	4.04e-05	0.000354	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	4.03e-05	0.00579	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KIT—testicular cancer	4.03e-05	0.00578	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—FGFR3—testicular cancer	4.02e-05	0.00576	CbGpPWpGaD
Temsirolimus—Skin disorder—Doxorubicin—testicular cancer	4.01e-05	0.000352	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—KIT—testicular cancer	4.01e-05	0.00575	CbGpPWpGaD
Temsirolimus—Dyspnoea—Epirubicin—testicular cancer	3.98e-05	0.000349	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—testicular cancer	3.97e-05	0.000348	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	3.95e-05	0.00567	CbGpPWpGaD
Temsirolimus—Anorexia—Doxorubicin—testicular cancer	3.94e-05	0.000345	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Methotrexate—testicular cancer	3.9e-05	0.000342	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—testicular cancer	3.88e-05	0.00034	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—testicular cancer	3.85e-05	0.000338	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—testicular cancer	3.85e-05	0.000337	CcSEcCtD
Temsirolimus—Pain—Epirubicin—testicular cancer	3.82e-05	0.000335	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—testicular cancer	3.82e-05	0.000335	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—FGFR3—testicular cancer	3.8e-05	0.00545	CbGpPWpGaD
Temsirolimus—Abdominal pain—Methotrexate—testicular cancer	3.77e-05	0.00033	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—testicular cancer	3.77e-05	0.00033	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	3.77e-05	0.00541	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KIT—testicular cancer	3.77e-05	0.00541	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KIT—testicular cancer	3.77e-05	0.00541	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KITLG—testicular cancer	3.76e-05	0.0054	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—testicular cancer	3.76e-05	0.00033	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—testicular cancer	3.74e-05	0.000327	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—KIT—testicular cancer	3.74e-05	0.00536	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KIT—testicular cancer	3.7e-05	0.00532	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KIT—testicular cancer	3.69e-05	0.00529	CbGpPWpGaD
Temsirolimus—Dyspnoea—Doxorubicin—testicular cancer	3.68e-05	0.000323	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—testicular cancer	3.67e-05	0.000322	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Epirubicin—testicular cancer	3.65e-05	0.00032	CcSEcCtD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.64e-05	0.00523	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	3.64e-05	0.00522	CbGpPWpGaD
Temsirolimus—Decreased appetite—Doxorubicin—testicular cancer	3.59e-05	0.000315	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.57e-05	0.000312	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—testicular cancer	3.56e-05	0.000312	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—BCL10—testicular cancer	3.56e-05	0.00511	CbGpPWpGaD
Temsirolimus—Pain—Doxorubicin—testicular cancer	3.53e-05	0.00031	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—testicular cancer	3.53e-05	0.00031	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—testicular cancer	3.53e-05	0.000309	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—testicular cancer	3.53e-05	0.000309	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—testicular cancer	3.52e-05	0.000308	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—KIT—testicular cancer	3.49e-05	0.00501	CbGpPWpGaD
Temsirolimus—Asthenia—Methotrexate—testicular cancer	3.42e-05	0.0003	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—BCL10—testicular cancer	3.42e-05	0.00491	CbGpPWpGaD
Temsirolimus—CYP2D6—Biological oxidations—HPGDS—testicular cancer	3.41e-05	0.0049	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Doxorubicin—testicular cancer	3.38e-05	0.000296	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—testicular cancer	3.38e-05	0.000296	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	3.34e-05	0.00479	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	3.33e-05	0.00478	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Epirubicin—testicular cancer	3.29e-05	0.000288	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—testicular cancer	3.27e-05	0.000286	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—testicular cancer	3.27e-05	0.000286	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—testicular cancer	3.26e-05	0.000286	CcSEcCtD
Temsirolimus—Asthenia—Epirubicin—testicular cancer	3.2e-05	0.000281	CcSEcCtD
Temsirolimus—Pruritus—Epirubicin—testicular cancer	3.16e-05	0.000277	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—testicular cancer	3.16e-05	0.000276	CcSEcCtD
Temsirolimus—Diarrhoea—Epirubicin—testicular cancer	3.06e-05	0.000268	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—testicular cancer	3.04e-05	0.000267	CcSEcCtD
Temsirolimus—Vomiting—Methotrexate—testicular cancer	3.03e-05	0.000266	CcSEcCtD
Temsirolimus—Rash—Methotrexate—testicular cancer	3.01e-05	0.000264	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—testicular cancer	3.01e-05	0.000263	CcSEcCtD
Temsirolimus—Headache—Methotrexate—testicular cancer	2.99e-05	0.000262	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—testicular cancer	2.96e-05	0.00026	CcSEcCtD
Temsirolimus—Dizziness—Epirubicin—testicular cancer	2.95e-05	0.000259	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—testicular cancer	2.92e-05	0.000256	CcSEcCtD
Temsirolimus—Vomiting—Epirubicin—testicular cancer	2.84e-05	0.000249	CcSEcCtD
Temsirolimus—Nausea—Methotrexate—testicular cancer	2.83e-05	0.000248	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—testicular cancer	2.83e-05	0.000248	CcSEcCtD
Temsirolimus—Rash—Epirubicin—testicular cancer	2.82e-05	0.000247	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—testicular cancer	2.81e-05	0.000246	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—FGFR3—testicular cancer	2.8e-05	0.00401	CbGpPWpGaD
Temsirolimus—Headache—Epirubicin—testicular cancer	2.8e-05	0.000245	CcSEcCtD
Temsirolimus—MTOR—Signaling Pathways—INSL3—testicular cancer	2.75e-05	0.00394	CbGpPWpGaD
Temsirolimus—Dizziness—Doxorubicin—testicular cancer	2.73e-05	0.000239	CcSEcCtD
Temsirolimus—Nausea—Epirubicin—testicular cancer	2.65e-05	0.000232	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—testicular cancer	2.63e-05	0.00023	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—testicular cancer	2.6e-05	0.000228	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—testicular cancer	2.6e-05	0.000228	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—testicular cancer	2.59e-05	0.000227	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—KIT—testicular cancer	2.57e-05	0.00369	CbGpPWpGaD
Temsirolimus—Nausea—Doxorubicin—testicular cancer	2.45e-05	0.000215	CcSEcCtD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.42e-05	0.00347	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—H2AFZ—testicular cancer	2.23e-05	0.0032	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.23e-05	0.0032	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KITLG—testicular cancer	2.15e-05	0.00308	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BCL10—testicular cancer	2.07e-05	0.00298	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KITLG—testicular cancer	2.06e-05	0.00296	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KITLG—testicular cancer	2.05e-05	0.00295	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—FGFR3—testicular cancer	1.6e-05	0.00229	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—H2AFZ—testicular cancer	1.56e-05	0.00224	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STK11—testicular cancer	1.55e-05	0.00223	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FGFR3—testicular cancer	1.53e-05	0.0022	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FGFR3—testicular cancer	1.53e-05	0.00219	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KIT—testicular cancer	1.46e-05	0.0021	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KITLG—testicular cancer	1.44e-05	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KIT—testicular cancer	1.41e-05	0.00202	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KIT—testicular cancer	1.4e-05	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Disease—H2AFZ—testicular cancer	1.25e-05	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KITLG—testicular cancer	1.25e-05	0.00179	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KITLG—testicular cancer	1.15e-05	0.00166	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HPGDS—testicular cancer	1.14e-05	0.00163	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FGFR3—testicular cancer	1.07e-05	0.00153	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KIT—testicular cancer	9.81e-06	0.00141	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FGFR3—testicular cancer	9.29e-06	0.00133	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—H2AFZ—testicular cancer	8.79e-06	0.00126	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STK11—testicular cancer	8.74e-06	0.00125	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FGFR3—testicular cancer	8.58e-06	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KIT—testicular cancer	8.53e-06	0.00122	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—STK11—testicular cancer	8.25e-06	0.00118	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HPGDS—testicular cancer	8.2e-06	0.00118	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KITLG—testicular cancer	8.08e-06	0.00116	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KIT—testicular cancer	7.88e-06	0.00113	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HPGDS—testicular cancer	6.19e-06	0.000889	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGFR3—testicular cancer	6.01e-06	0.000862	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—STK11—testicular cancer	5.96e-06	0.000856	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HPGDS—testicular cancer	5.83e-06	0.000837	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—testicular cancer	5.52e-06	0.000792	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—STK11—testicular cancer	4.5e-06	0.000646	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—STK11—testicular cancer	4.24e-06	0.000608	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPGDS—testicular cancer	3.81e-06	0.000547	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—STK11—testicular cancer	2.77e-06	0.000398	CbGpPWpGaD
